Jasper’s Expanding Pipeline
Jasper maintains worldwide rights to develop and commercialize Briquilimab and Jasper mRNA Stem Cell Grafts in all indications.
Briquilimab (JSP191)
- Low to Intermediate Risk MDS Therapeutic
- Chronic Urticaria
- SCID
- AML/MDS
- Fanconi Anemia
- Sickle Cell Disease
- CGD
- GATA2 MDS
- Gene Therapy – Gaucher Disease
- Gene Therapy – X-SCID
Jasper mRNA Stem Cell Graft Platform
- Thalassemias, Sickle Cell Disease
- Autoimmune Diseases
MDS: Myelodysplastic Syndrome
SCID: Severe Combined Immunodeficiency
AML: Acute Myeloid Leukemia
CGD: Chronic Granulomatous Disease
GATA2 MDS: MDS with germline GATA2 mutations
X-SCID: X-Linked SCID
EXPANDED ACCESS
Jasper is a clinical stage biotechnology company focused on the development of novel curative therapies by focusing on the biology of the hematopoietic stem cell. Jasper’s lead program, Briquilimab, is an investigational therapy currently being studied in multiple clinical trials for serious and life-threatening conditions. Participation in a clinical trial of Briquilimab is the best way to access Briquilimab investigational therapy. Jasper does not currently provide access to our investigational therapies under Expanded Access.